| Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing J Zhang, J Fujimoto, J Zhang, DC Wedge, X Song, J Zhang, S Seth, ... Science 346 (6206), 256-259, 2014 | 1015 | 2014 |
| Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial AT Shaw, L Gandhi, S Gadgeel, GJ Riely, J Cetnar, H West, DR Camidge, ... The lancet oncology 17 (2), 234-242, 2016 | 701 | 2016 |
| Osimertinib in pretreated T790M-positive advanced non–small-cell lung cancer: AURA study phase II extension component JCH Yang, MJ Ahn, DW Kim, SS Ramalingam, LV Sequist, WC Su, ... Journal of Clinical Oncology 35 (12), 1288-1296, 2017 | 580 | 2017 |
| Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer M Reck, A Luft, A Szczesna, L Havel, SW Kim, W Akerley, MC Pietanza, ... Journal of Clinical Oncology 34 (31), 3740-3748, 2016 | 514 | 2016 |
| Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial SN Gettinger, LA Bazhenova, CJ Langer, R Salgia, KA Gold, R Rosell, ... The Lancet Oncology 17 (12), 1683-1696, 2016 | 359 | 2016 |
| Eat and exercise during radiotherapy or chemoradiotherapy for pharyngeal cancers: use it or lose it KA Hutcheson, MK Bhayani, BM Beadle, KA Gold, EH Shinn, SY Lai, ... JAMA otolaryngology–head & neck surgery 139 (11), 1127-1134, 2013 | 236 | 2013 |
| Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology AKP Ganti, BW Loo, M Bassetti, C Blakely, A Chiang, TA D'Amico, ... Journal of the National Comprehensive Cancer Network 19 (12), 1441-1464, 2021 | 182 | 2021 |
| Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer PA Jänne, C Baik, WC Su, ML Johnson, H Hayashi, M Nishio, DW Kim, ... Cancer discovery 12 (1), 74-89, 2022 | 163 | 2022 |
| Targeted therapies in squamous cell carcinoma of the head and neck KA Gold, HY Lee, ES Kim Cancer: Interdisciplinary International Journal of the American Cancer …, 2009 | 163 | 2009 |
| Relationship between tumor size and survival in non–small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry J Zhang, KA Gold, HY Lin, SG Swisher, Y Xing, JJ Lee, ES Kim, ... Journal of Thoracic Oncology 10 (4), 682-690, 2015 | 156 | 2015 |
| Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial AG Sacco, R Chen, FP Worden, DJL Wong, D Adkins, P Swiecicki, ... The Lancet Oncology 22 (6), 883-892, 2021 | 144 | 2021 |
| Exploratory analysis of brigatinib activity in patients with anaplastic lymphoma kinase-positive non–small-cell lung cancer and brain metastases in two clinical trials DR Camidge, DW Kim, M Tiseo, CJ Langer, MJ Ahn, AT Shaw, RM Huber, ... Journal of Clinical Oncology 36 (26), 2693-2701, 2018 | 144 | 2018 |
| Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non–small-cell lung cancer after neoadjuvant chemotherapy WN William Jr, A Pataer, N Kalhor, AM Correa, DC Rice, II Wistuba, ... Journal of Thoracic Oncology 8 (2), 222-228, 2013 | 123 | 2013 |
| Selective antitumor activity of ibrutinib in EGFR-mutant non–small cell lung cancer cells W Gao, M Wang, L Wang, H Lu, S Wu, B Dai, Z Ou, L Zhang, JV Heymach, ... Journal of the National Cancer Institute 106 (9), dju204, 2014 | 111 | 2014 |
| Immune modulation of head and neck squamous cell carcinoma and the tumor microenvironment by conventional therapeutics S Miyauchi, SS Kim, J Pang, KA Gold, JS Gutkind, JA Califano, LK Mell, ... Clinical Cancer Research 25 (14), 4211-4223, 2019 | 108 | 2019 |
| Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: a single‐arm phase 2 clinical trial KA Gold, MS Kies, WN William Jr, FM Johnson, JJ Lee, BS Glisson Cancer 124 (10), 2169-2173, 2018 | 105 | 2018 |
| Safety and efficacy of pembrolizumab with chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a phase IB study SF Powell, KA Gold, MM Gitau, CJ Sumey, MM Lohr, SC McGraw, ... Journal of Clinical Oncology 38 (21), 2427, 2020 | 98 | 2020 |
| Probing the building blocks of eumelanins using scanning electron microscopy JB Nofsinger, SE Forest, LM Eibest, KA Gold, JD Simon Pigment Cell Research 13 (3), 179-184, 2000 | 98 | 2000 |
| Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma Y Xing, J Zhang, H Lin, KA Gold, EM Sturgis, AS Garden, JJ Lee, ... Cancer 122 (4), 534-545, 2016 | 94 | 2016 |
| Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non–small cell lung cancer (NSCLC). DR Camidge, L Bazhenova, R Salgia, CJ Langer, KA Gold, R Rosell, ... Journal of Clinical Oncology 33 (15_suppl), 8062-8062, 2015 | 80 | 2015 |
